The slow-acting, symptom modifying effects of colchicine in primary knee osteoarthritis
DOI:
https://doi.org/10.15305/ijrci/v4i1/189Keywords:
colchicine, etodolac, osteoarthritis, knee jointniAbstract
Aim: To determine whether the therapeutic use of colchicine along with etodolac (selective cox-2 inhibitor NSAIDs) confer any beneficial effect in the treatment of osteoarthritis of knee joint.
Materials and methods: Forty selected subjects were randomized to receive either 0.5 mg of colchicine twice daily or placebo for 26 weeks.
Results: Visual analog scale (VAS), Western Ontario and McMaster University Osteoarthritis total scale (WOMAC), and patient global assessment and physician global assessment scores were recorded on day 0, weeks 2, 6, 10, 14, 18, 22 and 26. Improvement rate at the end of 22 week was higher in colchicine group than placebo, as measured by VAS score (46.88 vs.51.11;P=0.033), WOMAC score (18.88 vs.24.56; P=0.019), patient global assessment score(34.69 vs. 38.33; P=0.039) and physician global assessment score (20.00 vs. 26.39; P=0.02).
Conclusion: Subjects receiving colchicine plus etodolac exhibited significantly better symptom control at the end of 22 weeks than the placebo group.
References
Lindblad S, Hedfors E. Arthroscopic and immunohistologic characterization of knee joint synovitis in osteoarthritis. Arthritis rheum. 1987;30:1081-1088.
Martin JA, Buckwalter JA: Aging, articular cartilage chondrocyte senescene and osteoarthritis. Biogerontology. 2002;3(5):257-64.
Wluka AE, Cicutini FM, Spector TD. Menopause, oestrogens and arthritis, Maturitas. 2000 Jun 30;35(3):183-99.
Newman B, Wallis GA. Is osteoarthritis a genetic disease? Clin Invest Med. 2002 Aug;25(4):139-49.
Anderson JJ, Felson DT. Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES-1), Evidence for an association with overweight race and physical demands of work. Am J Epidemiol. 1988 Jul;128(1):179-89.
Hunter DJ, March L, Sambrook PN. Knee osteoarthritis the influence of environmental factors, Clin Exp Rheumatol. 2002 Jan-Feb;20(1):93-100.
Das SK, Ramakrishnan S, Mishra K, Srivastava R, Agarwal GG, Singh R, et al. A randomized control trial to evaluate the slow acting symptom modifying effects of colchicine in osteoarthritis of the knee. A preliminary report. Arthritis Rheum. 2002;47(3):280-4.
Das SK, Chandra A, Sahani K, Sircar AR. A preliminary clinical trial to assess short term symptom modifying effect of a regimen containing colchicine in a selected subset of patients with osteoarthritis knee. J Ind Rheum Assoc. 1999; 7: 8–11.
Dieppe P, Crocker P, Corke C, Doyle D, Huskisson E, Willoughby D. Synovial fluid crystals. Quarterly J Med. 1979;48:533–55.
Gibilisco P, Schumacher HJ,Hollander J, Soper K. Synovial fluid crystals in osteoarthritis. Arthritis Rheum. 1984; 28:511-515.
Rosenthal A. Update in calcium deposition diseases. Curr Opin in Rheumatol 2007;19:158-162.
Pelletier J, Martell- Palletier J. Evidence for involvement of interleukin 1 in human osteoarthritic cartilage degradation: protective effects of NSAID. J Rheumatol 1989;16:19-27.
Cooke T. Immune pathology in polyarticular osteoarthritis. Clinical Orthop Ril Res 1986; 213:41-49.
Oehler S, Neureiter D, Mayer-Scholten C, Aigner T. Subtyping of osteoarthritic synoviopathy. 2002 Sep-Oct;20(5):633-40.
Zhang G, Hui W,Litherland G, Barter MJ, Davidson R, Darrah C, et al. Differential toll like receptor dependent collagenase expression in chondrocytes. Ann Rheu Dis 2008; 67:1633-1641.
Honig EG, Ingram RH. Chronic bronchitis, emphysema, and airway obstruction. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison’s principles of internal medicine. 14th ed. International edition: McGraw-Hill; 1998. p. 1451–60.
Jean-Pierre Pelletier, Martell-Pelletier J, Howel DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 13th ed.Philadelphia: Williams & Wilkins; 1997. p. 1969–84.
Honig EG, Ingram RH. Chronic bronchitis, emphysema, and airway obstruction. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, et al, editors. Harrison’s principles of internal medicine. 14th ed. International edition: McGraw-Hill; 1998. p. 1451–60.
Published
Issue
Section
License
Copyright for articles published in this journal is retained by the authors, with first publication rights granted to the ‘Internet Journal of Rheumatology and Clinical Immunology’. All the published content, except where otherwise noted, is licensed under Creative Commons license (CC-BY).
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) after the publication of the manuscript in IJRCI, as it can lead to productive exchanges, as well as earlier and greater citation of published work.